Despite strong revenue growth in the past, Denali Therapeuti...

Despite strong revenue growth in the past, Denali Therapeutics' lower than average P/S ratio is due to investor expectations of diminishing performance. The inferior revenue forecasts for Denali compared to its industry might continue to suppress its share price.